Rheumatoid arthritis (RA) is an autoimmune disease in which the immune system attacks joint linings, causing chronic inflammation, pain, and joint destruction. It typically affects small joints of hands and feet symmetrically and can spread to larger joints. Early aggressive treatment prevents permanent damage.
Disease-modifying antirheumatic drugs (DMARDs)—methotrexate, sulfasalazine, leflunomide—slow disease progression and joint erosion. Biologic DMARDs—TNF inhibitors (adalimumab, infliximab, etanercept), IL-6 inhibitors (tocilizumab), and JAK inhibitors (baricitinib, tofacitinib)—target specific immune pathways; combination therapy is common. Glucocorticoids (low-dose prednisone) provide short-term symptom relief. NSAIDs reduce pain and inflammation. Physiotherapy, occupational therapy, and splinting maintain function. Remission or low disease activity is the treatment goal; remission rates exceed 50% with modern therapy.
Ginger, turmeric (curcumin), fish oil, and herbal remedies (devil's claw, boswellia) show weak evidence; they may provide mild symptom relief but do not replace DMARDs. Homeopathy, acupuncture, and Chinese medicine lack robust trials.
Stem cell therapy is investigated for its anti-inflammatory and tissue-regenerative potential. Mesenchymal stem cells have shown promise in early trials, reducing pain and improving joint function in some patients. Clinical evidence is limited; regenerative approaches are not standard and should not delay established DMARD therapy.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Methotrexate (DMARD) | Standard | Strong | €50–120/month | Low | Weekly injection or oral; 8–12 weeks to effect; 60–70% respond well |
| TNF Inhibitors (Adalimumab, Infliximab) | Standard | Strong | €800–2,500/month | Low | Weekly/fortnightly injection or IV infusion; 4–8 weeks to effect; halts progression |
| IL-6 Inhibitors (Tocilizumab) | Standard | Strong | €1,500–3,000/month | Low | Weekly injection or monthly IV; excellent remission rates |
| JAK Inhibitors (Baricitinib, Tofacitinib) | Standard | Strong | €1,200–2,500/month | Low | Oral daily; rapid onset (days); remission in many patients |
| Low-Dose Glucocorticoids (Prednisone) | Standard | Strong | €20–50/month | Low | Rapid symptom relief; adjunct to DMARDs; used short-term |
| NSAIDs (Ibuprofen, Naproxen) | Standard | Strong | €20–60/month | Low | Rapid pain relief; used with gastric protection |
| Mesenchymal Stem Cell Intra-articular Injection | Regenerative | Moderate | €8,000–15,000 per joint | Medium | 1–2 weeks; pain reduction in some; cartilage regeneration modest |
| Physiotherapy & Occupational Therapy | Standard | Strong | €60–100/session | Low | Ongoing; maintains joint mobility and function |
Yes. With methotrexate plus biologic therapy, 50–60% of patients achieve sustained remission or low disease activity. Joint damage halts; some patients eventually taper medications. Early aggressive treatment maximises remission chances.
No. Mesenchymal stem cells reduce pain and inflammation in some joint studies but do not suppress systemic autoimmunity. DMARDs—especially biologics—are essential for halting progression and achieving remission.
Untreated RA causes progressive joint erosion, deformity, and disability within months to years. Early diagnosis and DMARD therapy prevent this; remission rates have improved dramatically over the past two decades.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
GMP-сертифицирана регенеративна медицина в сърцето на ЕС — от 3 000–8 000 €, част от цените в САЩ или Германия. Персонализирани протоколи за пациенти от над 50 държави.
Безплатна медицинска оценка